Serum M30 levels are associated with survival in advanced gastric carcinoma patients

International Immunopharmacology

Volumn 10, Issue 7, 2010, Pages 719-722

  Yaman, Emel ^a   Coskun, Ugur ^b   Sancak, Banu ^b   Buyukberber, Suleyman ^b   Ozturk, Banu ^b   Benekli, Mustafa ^b  

^a MERSIN STATE HOSPITAL   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Gastric cancer; Serum M30 level; Serum M65 levels

Indexed keywords

CASPASE; CYTOKERATIN 18; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M30; MONOCLONAL ANTIBODY M65; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; STOMACH CARCINOMA; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA; CASPASES; FEMALE; HUMANS; KERATIN-18; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 77953027428     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.03.013     Document Type: Article

References (24)

1. Lane E.B., and Alexander C.M. Use of keratin antibodies in tumor diagnosis. Semin Cancer Biol 1 (1990) 165-179
2. Sheard M.A., Vojtesek B., Simickova M., and Valik D. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem 85 (2002) 670-677
3. Ueno T., Toi M., and Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 59 Suppl 2 (2005) S359-S362
4. Leers M.P., Kolgen W., Bjorklund V., et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187 (1999) 567-572
5. Kramer G., Erdal H., Mertens H.J., et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64 (2004) 1751-1756
6. Galluzzi L., Maiuri M.C., Vitale I., Zischka H., Castedo M., Zitvogel L., et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 14 (2007) 1237-1243
7. Demiray M., Ulukaya E.E., Arslan M., et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest 24 (2006) 669-676
8. Ueno T., Toi M., Biven K., Bando H., Ogawa T., and Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 39 (2003) 769-774
9. Ulukaya E., Yilmaztepe A., Akgoz S., Linder S., and Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 56 (2007) 399-404
10. Olofsson M.H., Ueno T., Pan Y., et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13 (2007) 3198-3206
11. Wu Y.X., Wang J.H., Wang H., and Yang X.Y. Study on expression of Ki-67, early apoptotic protein M30 in endometrial carcinoma and their correlation with prognosis. Zhonghua Bing Li Xue Za Zhi 32 (2003) 314-318
12. Cummings J., Hodgkinson C., Odedra R., et al. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol Cancer Ther 7 (2008) 455-463
13. Abe T., Fukumoto M., Tsuchiya K., et al. Human monoclonal antibodies against cytokeratin 18 generated from patients with gastric cancer. Jpn J Cancer Res 80 (1989) 271-276
14. Xu W., Zhang M.W., Huang J., Wang X., Xu S.F., Li Y., et al. Correlation between CK18 gene and gastric carcinoma micrometastasis. World J Gastroenterol 11 (2005) 6530-6534
15. Greene F.L.P.D., and Fleming I.D. American Joint Committee on Cancer Staging Manual. 6th ed (2002), Springer, Philadelphia
16. Greystoke A., Cummings J., Ward T., et al. Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 19 (2008) 990-995
17. Caulin C., Salvesen G.S., and Oshima R.G. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138 (1997) 1379-1394
18. de Haas E.C., di Pietro A., Simpson K.L., et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 10 (2008) 1041-1048
19. Biven K., Erdal H., Hagg M., et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 8 (2003) 263-268
20. Kramer G., Schwarz S., Hagg M., Havelka A.M., and Linder S. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 94 (2006) 1592-1598
21. Ku N.O., Liao J., and Omary M.B. Apoptosis generates stable fragments of human type I keratins. J Biol Chem 272 (1997) 33197-33203
22. Koelink P.J., Lamers C.B., Hommes D.W., and Verspaget H.W. Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer 9 23 (2009) 88
23. Scott L.C., Evans T.R., Cassidy J., Harden S., Paul J., Ullah R., et al. Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br J Cancer 101 3 (2009) 410-417
24. Brandt D., Volkmann X., Anstätt M., Länger F., Manns M.P., Schulze-Osthoff K., et al. Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomas. Eur J Cancer (Mar 2 2010) [Electronic publication ahead of print]